finance.yahoo.com Deals and strategy
Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn). The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares. Completion of the deal is anticipated towards the end of this year, contingent on meeting a minimum acceptance threshold of …